TG Therapeutics Inc (TG Therapeutics) develops products for the treatment of B-cell malignancies and various autoimmune diseases. Its lead product candidate Briumvi (ublituximab- xiiy) is a chimeric, glycoengineered monoclonal antibody, which targets a specific and unique epitope on the CD20 antigen that is present on the surface of B-lymphocytes. The B-cell depleting effects are through three mechanisms: complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC) and direct or programmed cell death (DCD or PCD).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

TG Therapeutics has a major focus on its research and development operations for the development of novel monoclonal antibodies to treat various B-cell proliferative disorders including leukemia, lymphoma, and auto-immune diseases. In FY2023, the company spent US$63.2 million on R&D activities. Few of the pipeline products of the company in include; Ublituximab, TG-1801 and TG-1701. It is currently testing TG-1701 in patients with B-cell malignancies in a Phase 1 multi-center, dose-escalation clinical trial. TG-1801 is a first-in-class, bispecific CD47, and CD19 antibody.